VANDA Pharmaceuticals - Investor Relations - IR Home

Investor Relations

Press Releases

Print Page Print Page
<< Back
Vanda Pharmaceuticals Announces the Appointment of General Counsel

WASHINGTON, Aug. 13, 2018 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that it has named Timothy Williams as Vanda's Senior Vice President, General Counsel and Secretary.

"I am very pleased to welcome Tim to the Vanda executive management team," said Mihael H. Polymeropoulos, M.D., President and CEO of Vanda. "He is an exceptional leader and lawyer and brings a wealth of experience that we expect will prove instrumental as we continue to execute our global strategy."

Prior to joining Vanda, Mr. Williams served as Executive Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at AgNovos Healthcare, a medical device company focused on bone health. Prior to this position, Mr. Williams was Senior Legal Counsel and Assistant Secretary at Stryker Corporation, a global medical technology company, where he led the legal department's global M&A, corporate governance, and securities groups.

Before joining Stryker, Mr. Williams practiced law in Chicago at Mayer Brown LLP and Bryan Cave LLP. Mr. Williams received his Bachelor of Music and Masters of Music from Western Michigan University and his Juris Doctor from the University of Michigan.  

About Vanda Pharmaceuticals Inc.
Vanda is a global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda, please visit www.vandapharma.com.

Corporate Contact:
Jim Kelly 
Executive Vice President and Chief Financial Officer 
Vanda Pharmaceuticals Inc. 
(202) 734-3428 
jim.kelly@vandapharma.com  

Cision View original content:http://www.prnewswire.com/news-releases/vanda-pharmaceuticals-announces-the-appointment-of-general-counsel-300696199.html

SOURCE Vanda Pharmaceuticals Inc.

Copyright © 2005-2024 Vanda Pharmaceuticals Inc. |